Rescreening as a quality control procedure in cytopathology.
Many cytopathologists regard the 10% rescreening regulation of the Center for Disease Control and Social Security Administration as an unsatisfactory procedure for internal monitoring of cytoscreener performance. The principal deficiencies actually lie in the lack of specified performance criteria and an associated decision rule. By specifying these mission elements of a monitoring strategy are obtained as attribute acceptance sampling plans. The acceptance sampling approach to monitoring cytoscreener performance by rescreening "negative" slides id discussed.